Last reviewed · How we verify
Joicela (LUMIRACOXIB)
Joicela (generic name: LUMIRACOXIB) is a lumiracoxib Small molecule drug developed by Novartis Pharmaceuticals UK Limited. It is currently FDA-approved (first approved 2005) for Osteoarthritis.
Lumiracoxib (Joicela), marketed by Novartis Pharmaceuticals UK Limited, is a selective inhibitor of Prostaglandin G/H synthase 1, primarily indicated for osteoarthritis. Its key strength lies in its selective mechanism, which may offer a favorable safety profile compared to non-selective NSAIDs. The primary risk is the upcoming key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | LUMIRACOXIB |
|---|---|
| Sponsor | Novartis Pharmaceuticals UK Limited |
| Drug class | lumiracoxib |
| Target | Prostaglandin G/H synthase 1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2005 |
Approved indications
- Osteoarthritis
Common side effects
Key clinical trials
- Efficacy of Lumiracoxib in Relieving Moderate to Severe Post-dental Surgery Pain, Compared to Both Placebo and Celecoxib (PHASE4)
- Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension (PHASE4)
- Safety Study of Renal Function in Patients With Chronic Kidney Failure Taking Lumiracoxib or Diclofenac for Arthralgia (PHASE2)
- 52 Week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability & Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid & Celecoxib 200 mg od in Pts With Primary OA of Hip, Knee, Hand or Spine (PHASE3)
- Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA) (PHASE3)
- Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA) (PHASE3)
- Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis (PHASE3)
- 6 Week Open-label Trial With Lumiracoxib 200mg o.d. in Primary Knee Osteoarthritis or Rheumatoid Arthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Joicela CI brief — competitive landscape report
- Joicela updates RSS · CI watch RSS
- Novartis Pharmaceuticals UK Limited portfolio CI
Frequently asked questions about Joicela
What is Joicela?
What is Joicela used for?
Who makes Joicela?
What is the generic name of Joicela?
What drug class is Joicela in?
When was Joicela approved?
What development phase is Joicela in?
What does Joicela target?
Related
- Drug class: All lumiracoxib drugs
- Target: All drugs targeting Prostaglandin G/H synthase 1
- Manufacturer: Novartis Pharmaceuticals UK Limited — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Osteoarthritis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing